Published in Thromb Haemost on October 01, 2006
The management of hemophilia in elderly patients. Clin Interv Aging (2007) 1.04
Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfus (2008) 0.87
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Hematol (2015) 0.80
Joining the patient on the path to customized prophylaxis: one hemophilia team explores the tools of engagement. J Multidiscip Healthc (2015) 0.75
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B. J Blood Med (2016) 0.75
D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med (2006) 6.62
Acquired hemophilia A: a concise review. Am J Hematol (2005) 2.35
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost (2013) 2.19
Recommendations for the transfusion of red blood cells. Blood Transfus (2009) 1.85
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol (2005) 1.63
Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus (2009) 1.62
Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. J Thromb Haemost (2012) 1.57
How I treat rare venous thromboses. Blood (2008) 1.56
Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica (2002) 1.54
Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol (2004) 1.52
Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone (2006) 1.50
Quality and reliability of routine coagulation testing: can we trust that sample? Blood Coagul Fibrinolysis (2006) 1.50
Effects on health of air pollution: a narrative review. Intern Emerg Med (2015) 1.48
The syndrome of the "obsessive-compulsory scientist": a new mental disorder? Clin Chem Lab Med (2013) 1.47
Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period. Blood Transfus (2011) 1.45
Recommendations for the transfusion of plasma and platelets. Blood Transfus (2009) 1.45
Together we care: new challenges for global haemophilia treatment centers. Indian J Med Res (2009) 1.44
Routine coagulation tests in newborn and young infants. J Thromb Thrombolysis (2007) 1.42
Recombinant human erythropoietin facilitates autologous blood collections in children undergoing corrective spinal surgery. Transfusion (2004) 1.42
Phlebotomy issues and quality improvement in results of laboratory testing. Clin Lab (2006) 1.41
Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Semin Thromb Hemost (2009) 1.39
The growing impact of publications in haemostasis and thrombosis journals. Thromb Haemost (2007) 1.38
The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta (2008) 1.33
The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis (2010) 1.24
Prophylaxis in people with haemophilia. Thromb Haemost (2009) 1.19
Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes. Clin Chem Lab Med (2009) 1.19
An unusual case of a spurious, transfusion-acquired haemoglobin S. Blood Transfus (2010) 1.16
Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol (2011) 1.15
Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost (2012) 1.15
Haemorrhage and amyloidosis. Br J Haematol (2012) 1.14
Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol (2008) 1.12
Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med (2009) 1.11
Doping in competition or doping in sport? Br Med Bull (2008) 1.11
Influence of a light meal on routine haematological tests. Blood Transfus (2010) 1.10
Imatinib and regression of type 2 diabetes. N Engl J Med (2005) 1.09
The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med (2010) 1.06
Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus (2009) 1.05
Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". Semin Thromb Hemost (2010) 1.05
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance. Eur J Haematol Suppl (2008) 1.04
The management of hemophilia in elderly patients. Clin Interv Aging (2007) 1.04
Biochemistry, physiology, and complications of blood doping: facts and speculation. Crit Rev Clin Lab Sci (2006) 1.03
How to write a scientific manuscript for publication. Blood Transfus (2012) 1.02
Help me, Doctor! My D-dimer is raised. Ann Med (2008) 1.01
Mesenchymal stem cells: from biology to clinical use. Blood Transfus (2007) 1.00
Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost (2010) 1.00
Influenza and cardiovascular disease: does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both? Semin Thromb Hemost (2010) 0.99
Identification of spurious hemolysis in anticoagulated blood with Sysmex XE-2100 and Siemens Advia 2120. Clin Lab (2012) 0.98
Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica (2007) 0.97
Platelet gel in the treatment of cutaneous ulcers: the experience of the Immunohaematology and Transfusion Centre of Parma. Blood Transfus (2010) 0.96
Stability of blood cell counts, hematologic parameters and reticulocytes indexes on the Advia A120 hematologic analyzer. J Lab Clin Med (2005) 0.96
Determinants of anaemia in the very elderly: a major contribution from impaired renal function? Blood Transfus (2010) 0.96
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood (2013) 0.96
Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period. Blood Transfus (2011) 0.95
Diagnosis and management of ischemic heart disease. Semin Thromb Hemost (2013) 0.94
Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus (2009) 0.94
Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis (2011) 0.94
Old and new anticoagulant drugs: a minireview. Ann Med (2011) 0.94
Long-term persistence of molecular response after discontinuation of interferon-alpha in two patients with chronic myeloid leukaemia. Blood Transfus (2011) 0.94
Hemostasis, cancer, and ABO blood group: the most recent evidence of association. J Thromb Thrombolysis (2014) 0.94
Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. J Thromb Thrombolysis (2010) 0.93
Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis (2010) 0.93
Frequency and type of newly diagnosed haemoglobin variants in Northern Italy. Blood Transfus (2010) 0.92
TCF2 gene mutation leads to nephro-urological defects of unequal severity: an open question. Med Sci Monit (2008) 0.92
Thromboembolism in childhood nephrotic syndrome: a rare but serious complication. Hematology (2007) 0.92
Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease. Haematologica (2003) 0.92
Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol (2011) 0.91
Effectiveness of low-dose oral calcium carbonate for the prevention of citrate-related toxicity in peripheral blood stem cell collection. Blood Transfus (2011) 0.91
Non-O blood group: an important genetic risk factor for venous thromboembolism. Blood Transfus (2012) 0.91
Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia. Transfusion (2004) 0.91
Expression of CD27 and CD23 on peripheral blood B lymphocytes in humans of different ages. Blood Transfus (2009) 0.91
Acquired haemophilia A as a blood transfusion emergency. Blood Transfus (2008) 0.90
Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost (2012) 0.90
Comparison of serum creatinine, uric acid, albumin and glucose in male professional endurance athletes compared with healthy controls. Clin Chem Lab Med (2004) 0.90
Intensive blood transfusion support in acquired hemophilia A. Ann Hematol (2006) 0.90
Classic thrombophilic gene variants. Thromb Haemost (2015) 0.89
Genetic and biochemical heterogeneity of cardiac troponins: clinical and laboratory implications. Clin Chem Lab Med (2009) 0.89
Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev (2007) 0.89
Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost (2012) 0.89
Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care (2007) 0.88
Recommendations for the transfusion management of patients in the peri-operative period. III. The post-operative period. Blood Transfus (2011) 0.88
Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost (2011) 0.88
ABO blood group and von Willebrand factor: biological implications. Clin Chem Lab Med (2014) 0.87
Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfus (2008) 0.87
Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev (2009) 0.87
C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med (2010) 0.87
Blood doping by cobalt. Should we measure cobalt in athletes? J Occup Med Toxicol (2006) 0.87
Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis (2009) 0.87